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Abstract The objective of the study was to evaluate the
feasibility of a UK-based real-time service to improve the
diagnosis and management of lymphoproliferative disorders
(LPDs) in Ghana. Adult patients reporting to hospital with a
suspected LPD, during a 1 year period, were prospectively
enrolled. Bone marrow and/or lymph node biopsies were
posted to the Haematology Malignancy Diagnostic Service
(HMDS), Leeds, UK and underwent morphological analy-
sis and immunophenotyping. Results were returned by
e-mail. The initial diagnoses made in Ghana were compared
with the final HMDS diagnoses to assess the contribution
of the HMDS diagnosis to management decisions. The
study was conducted at the two teaching hospitals in
Ghana—Komfo Anokye, Kumasi and Korle Bu, Accra.
Participants comprised 150 adult patients (≥12 years old),
79 women, median age 46 years. Bone marrow and lymph
node biopsy samples from all adults presenting with
features suggestive of a LPD, at the two teaching hospitals
in Ghana, over 1 year were posted to a UK LPD diagnostic
centre, where immunophenotyping was performed by
immunohistochemistry. Molecular analysis was performed
where indicated. Diagnostic classifications were made
according to international criteria. Final diagnosis was
compared to the initial Ghanaian diagnosis to evaluate
discrepancies; implications for alterations in treatment
decisions were evaluated. Median time between taking
samples and receiving e-mail results in Ghana was 15 days.
Concordance between initial and final diagnoses was 32%
(48 of 150). The HMDS diagnosis would have changed
management in 31% (46 of 150) of patients. It is feasible to
provide a UK-based service for LPD diagnosis in Africa
using postal services and e-mail. This study confirmed
findings from wealthy countries that a specialised haema-
topathology service can improve LPD diagnosis. This
model of Ghana–UK collaboration provides a platform on
which to build local capacity to operate an international
quality diagnostic service for LPDs.
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Introduction
Understanding the genetic and molecular hallmarks of
lymphoproliferative disorders (LPDs) has led to many new
and highly efficacious therapeutic regimes. Accurate patho-
logical diagnosis and classification according to standard
criteria are essential first steps in determining appropriate
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Liverpool L3 5QA, UKtreatment strategies [1]. Accurate diagnosis of LPDs is
complex and discrepancies of 20–48% have been reported
between LPD diagnoses made by general histopathologists
and those made by specialist haematopathologists [2].
Diagnostic criteria use histological, immunological and
molecular techniques, combined with an ability to interpret
ambiguities associated with these techniques, and such
resources are generally not available in countries in sub-
Saharan Africa. However, initiatives such as health insurance
schemes mean that treatments for LPDs, such as chemother-
apeutic agents and radiotherapy, are increasingly available in
poorer countries, but they cannot be targeted effectively
because of inadequate capacity to accurately diagnose and
categorise LPDs.
LPDs are a heterogeneous group of neoplastic disorders of
the immune system, including lymphomas (non-Hodgkin and
Hodgkin), myeloma and lymphoid leukaemias. The inci-
dence, epidemiology and clinical presentation of LPDs vary
across the world because they are influenced by factors such
as genetic predisposition and environment [1, 3, 4]. This
means that knowledge about LPDs is not necessarily
transferable between regions and evidence about local LPD
patterns is needed to guide service delivery. For example,
one of the only prospective studies in sub-Saharan Africa
found a 1:3 male/female ratio in 60 patients with chronic
lymphocytic leukaemia (CLL) in Nigeria, which is strikingly
different to the usual 2:1 ratio seen in CLL in the west [5]. A
retrospective study in Kenya of 207 cases of non-Hodgkin
lymphoma that presented over 10 years found that 41% were
not properly classified histologically, and only 15% of 105
evaluable patients were followed up for at least 36 months
[6]. It is particularly important for clinical services in sub-
Saharan Africa to have the capacity to diagnose LPDs
because they may mimic infectious diseases especially
tuberculosis. A review of 129 lymph node biopsies from
Jos in Nigeria found that tuberculosis accounted for 48% of
the cases once sarcomas and carcinomas had been excluded
[7]. Rising HIV prevalence in Africa means that atypical
presentations of lymphoma and infections such as tubercu-
losis are increasing, and accurate diagnosis of lymphadenop-
athy will avoid misdiagnosis and inappropriate treatment of
infections and LPDs.
The purpose of this study was to assess the feasibility of
providing a UK-based real-time diagnostic service for
LPDs for two teaching hospitals in Ghana. The ultimate
goal is to strengthen the research opportunities and systems
in Ghana for investigating LPDs and to improve evidence-
based clinical care of LPDs. Collaborating institutions were
the Haematological Malignancy Diagnostic Service
(HMDS), Leeds, UK, and Komfo Anokye Teaching
Hospital (KATH), Kumasi and Korle Bu Teaching Hospital
(KBTH), Accra in Ghana. HMDS serves a population of
four million through the Yorkshire and Humberside Cancer
Networks and integrates morphological assessment,
immunophenotyping (by flow cytometry and/or immuno-
histochemistry) and molecular techniques to provide a ‘one-
stop’ service for diagnosis of haematological malignancies.
Results are double authorised by a combination of
consultant haematologists, haematopathologists and scien-
tists before release and e-mailed to clinicians via a
password-protected website. Better postal and e-mail
services between Ghana and the UK mean that it is now
potentially feasible to establish an off-site diagnostic
service through HMDS as a prelude to transferring the
service to the two Ghanaian teaching hospitals.
Methods
Study setting
The study was based in two teaching hospitals, KATH and
KBTH, in the two largest cities in Ghana. Patients were
referred to haematology and oncology clinics from within the
hospital or from regional and district hospitals and health
centres. Patients aged 12 years and above are seen in the adult
haematology clinics. Patients with suspected LPDs were
usually referred because of leucocytosis, abdominal mass or
lymphadenopathy. Prior to this study, patients were investi-
gatedandmanagedusingwhateverlocallyavailableresources
they could afford. Histopathology services were available in
KBTH. At KATH, fine-needle aspirates were interpreted on
site but biopsy samples were sent to be processed in private
histopathology laboratories.
To document the existing system for the diagnosis of
LPDs, a retrospective audit of the case notes of patients
referredtoKATH’shaematologyandoncologyclinicsin2004
(i.e. the year prior to the start of the study), with a suspected
diagnosis of LPD, was conducted. In order to capture all
potential LPD patients, the case notes of all patients with a
provisional diagnosis of lymphoma, leukaemia, myeloma,
splenomegaly or lymphadenopathy were reviewed, and data
were extracted about clinical features and laboratory results
using a pre-designed and piloted form.
New diagnostic service 2005–2006
For 1 year from March 2005, patients aged ≥12 years,
presenting to the hospitals’ haematology departments with
featuressuggestiveofaLPDwhogaveinformedconsentwere
enrolled in the study. Suggestive features included B
symptoms (fever, weight loss, sweats), lymphadenopathy,
hepatomegaly, splenomegaly, lymphocytosis, hypercalcaemia
and lytic bone lesions. Patients with splenomegaly were
entered only if they also had lymphocytosis, lymphadenopa-
thy or B symptoms or had failed to respond to proguanil
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available blood tests (e.g. blood count, lactate dehydroge-
nase, urea, creatinine and electrolytes, liver function tests,
calcium, erythrocyte sedimentation rate), X-rays, scans and
lymph node biopsies were performed as appropriate.
Peripheral blood (6 ml), 2 ml bone marrow aspirate and
trephine biopsy samples were taken from each patient.
Laboratory bench space, a centrifuge, a 37°C water bath and
freezer space were made available in each hospital for sample
processing. Consumablesweresourced locally inGhana apart
from eppendorfs, capped test tubes and pastettes.
An unstained bone marrow aspirate slide and trephine
biopsy for each patient, as well as the lymph node biopsy
samples, were posted to HMDS using United Postal
Services. Biopsy samples were fixed in formalin prior to
processing. At HMDS, immunophenotyping was performed
by immunohistochemistry on the trephine and lymph node
blocks. Standard streptavidin–biotin immunoperoxidase
methods were used to phenotype tumour cells using panels
of markers selected according to the suspected diagnosis
(Table 1). Immunophenotyping results were used in
conjunction with morphological and histological findings
to arrive at a final diagnosis according to WHO criteria [2].
Where relevant, fluorescence in situ hybridisation and
polymerase chain reaction analysis were also performed.
Results from HMDS were e-mailed to the Ghanaian
clinicians as soon as they had been authorised. Patients
were allocated a unique identification number, and all data
were entered onto a password-protected database. Only
project clinicians had access to patient data.
The initial diagnosis, based on clinical features and
locally available tests, was recorded for each patient. The
impact of HMDS results on patient diagnosis and hypo-
thetical implications for their management were evaluated
by comparing the HMDS diagnosis with the initial
diagnosis. Patients were divided into categories depending
on whether the initial diagnosis was the same as the final
HMDS diagnosis and whether the final diagnosis would
have altered patient management.
Ethics approval
The project received ethical approval from the ethics
committeesofLiverpoolSchoolofTropicalMedicine,Komfo
AnokyeTeachingHospital(Kumasi)andUniversityofGhana
Medical School (Accra). The project was discussed with
eligible patients, via an interpreter where necessary, using
specifically designed information and consent forms. Con-
senting patients (and guardians if they were less than 16 years
of age) signed or thumb-printed the form.
Results
Existing LPD services
Case notes were available for 63 of the 80 patients seen at
KATH in 2004 with a suspected LPD. The median age was
48 years (range 12–80 years) and 42 (67%) were female. B
symptoms (fever, sweats, significant weight loss) were
present in 26 (41%) patients. Forty-four patients (70%) had
splenomegaly (median 16 cm; range 4–26 cm), 27 (43%)
had hepatomegaly (median 6 cm; range 3–16 cm) and 18
(29%) had lymphadenopathy at presentation. Forty-eight of
63 (76%) diagnoses were made using clinical features
alone. Of these, 28 were hyper-reactive malarial spleno-
megaly and 19 were LPDs (Table 2). There were 11
cytological diagnoses—ten from fine needle aspirates and
one from a bone marrow aspirate. Only four diagnoses were
made histologically. Immunophenotyping and molecular
techniques were not involved in any of the diagnoses.
New diagnostic service 2005–2006
One hundred fifty patients, 117 from KATH and 33 from
KBTH, were entered into the study. There were 79
females, and the median age was 46 years (range
12–83 years). Their samples were sent to HMDS in 25
packages. Each package weighed less than 500 g and cost
£21.34/package. All parcels arrived intact at HMDS
within three to four working days of being posted. Four
packages, packed according to IATA regulations, were
carried by hand from Ghana to HMDS. The median time
between taking bone marrow trephine samples and
receiving e-mail results in Ghana was 15 days (range
7–62 days). For lymph node biopsy results, the median
time from samples leaving Ghana to results being e-
mailed back was 11 days (range 3–27).
Suspected tumour Markers
Lymphoma CD3 CD5 CD10 CD20 CD23 CD79 BCL2 BCL6 Ki67 Cyclin D1
Hodgkin lymphoma CD3 CD15 CD20 CD30 MUM1/IRF4 OCT2 BOB1
Acute lymphoblastic leukaemia CD1a CD3 CD7 CD10 CD34 CD79 PAX5 tdt
Myeloma CD138 CD56 MUM1/IRF4 kappa lambda
Carcinoma CD45 MNF116 CK7 CK20
Table 1 Panels of markers used
to phenotype tumour cells
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Pathological diagnosis was possible in 132 of the 150
patients. Specimens were not obtained in 14 patients due to
early death and loss to follow-up; only four patients had
inadequate specimens. Sixty-one of the132 patients (46%)
had a LPD, 42 (32%) had other diagnoses and 29 (22%)
had splenomegaly for which no cause could be found
(Table 3). Of the 61 LPD diagnoses, there were 30 non-
Hodgkin lymphomas (18 splenic marginal zone, four
diffuse large B-cell, three peripheral T-cell, two Burkitt,
two follicular and one mantle cell), seven Hodgkin
lymphomas (five nodular sclerosing, two mixed cellularity),
12 CLL, five acute lymphoblastic leukaemias (three T cell,
two B cell), six myelomas and one NK cell LPD.
Table 4 shows the initial diagnosis or differential
diagnosis made in Ghana before the HMDS result was
available. The HMDS diagnosis would not have signifi-
cantly affected management in 104 of 150 patients (69%).
In 48 patients (32%), the initial diagnosis was correct. In a
further 16 patients (11%), the final diagnosis was different
from the initial diagnosis but management would not have
been affected. The HMDS results did not affect diagnosis or
management in 40 patients (27%) because they were lost
from the study due to death or lack of data, a problem
frequently encountered in this setting (Table 5).
In 46 of 150 (31%) patients, the HMDS diagnosis would
have changed patient management. In half of these patients
(n=23), the HMDS diagnosis was part of the initial
differential diagnosis but it would not have been possible
to make to appropriate treatment decisions without the
additional results. In a further 23 patients, the HMDS
diagnosis was not part of the initial differential diagnosis. In
a third of patients (15 of 46) in whom the HMDS diagnosis
would have altered management, the initial diagnosis was
based on fine-needle aspirate cytology (Tables 4 and 5).
Discussion
This study demonstrates that it is feasible to provide a
sophisticated UK-based real-time LPD diagnostic service
for patients in Ghana using complex haemato-pathological
techniques. The service provides an interim solution until
Table 3 Characteristics of study patients
Diagnosis Number of patients
with diagnosis
a
Age years median
(range)
Sex
M/F
% patients with B
symptoms at presentation
WCC×10
9/l
median (range)
Total=132
Lymphoproliferative disorders 61 58 (12–80) 25:36 93 18.4 (1.5–UR)
Other
b or unknown diagnoses 42 33.5 (12–83) 25:17 83 7.4 (2–240)
Splenomegaly—unknown cause 29 35 (12–70) 13:16 93 3.3 (1–26.1)
UR unrecordable
aEighteen patients had no/inadequate trephine biopsy and have been excluded from the table
bAcute myeloid leukaemia, refractory anaemia with excess blasts, monoclonal gammopathy of uncertain significance, tuberculosis, Rosai
Dorfman, other malignancy, reactive marrow
Table 2 Case note diagnoses in patients with suspected LPD: 2004 audit
Diagnosis Number of patients
with diagnosis
Diagnosis made on
clinical features alone
Diagnosis made on
fine-needle aspirate
Diagnosis made
on biopsy
Diagnosis made on bone
marrow aspirate
HMS 28 28
NHL 13 6 5 2
HL 5 3 2
LPD 5 5
a
CLL 5 5
Myeloma/plasmacytoma 4 2 1 1
All 1 1
Portal hypertension 1 1
Metastatic malignancy 1 1
Total 63 48 10 4 1
HMS hyper-reactive malarial splenomegaly, NHL non-Hodgkin lymphoma, HL Hodgkin lymphoma, CLL chronic lymphocytic leukaemia, ALL
acute lymphoblastic leukaemia
aOne had had a biopsy, but result was not available
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diagnostic systems. The quality of samples transported to
the UK was good, and the turnaround time was 10–15 days.
The service depended on a few critical factors: a dedicated
team in each hospital, reliable communications between
institutions in Ghana and the UK and an efficient clinical
coordinator. The coordinator’s role was to ensure the
quality of samples, process and document specimens,
organise transport and receive and disseminate results.
The HMDS service enhanced the capability of the
existing service in Ghana to accurately diagnose suspected
LPDs. Overall HMDS diagnosis would have changed
management in a third of patients, confirmed initial
diagnosis in a third, and had no effect on management in
the other third. These results are similar to those from a
Welsh study, which found that a panel of specialist
haematopathologists disagreed with the initial diagnosis,
which would have altered subsequent management in 46%
of suspected LPD cases [2]. Our study provided prelimi-
nary information about the prevalence of different types of
lymphoma presenting to the hospital, which will enable
clinicians to make informed and rational choices about
treatment regimes. The collaboration between the Ghanaian
institutions and HMDS provided an excellent framework
for epidemiological studies and for detailed genetic and
molecular genetic assessments in selected patients such as
fluorescence in situ hybridisation and immunoglobulin gene
sequencing [9].
The success of the system was dependent on good record
keeping and effective communication systems between the
Ghanaian and UK institutions. It would have been unethical
to have withheld appropriate treatment once the HMDS
Table 5 Impact of HMDS diagnosis on patient management
Group
(N)
Initial diagnosis Effect of final HMDS diagnosis
on patient management
Examples
1 (48) Correct diagnosis Initial diagnosis confirmed;
no alteration in management
Hodgkin disease
Rosai Dorfman
2 (23) No firm diagnosis made; correct final
diagnosis included in differential diagnosis
HMDS diagnosis altered
management
NR
3 (16) Final diagnosis not included in initial
differential diagnosis
Final diagnosis did not
affect management
NK cell leukaemia
4 (23) Final diagnosis not included in initial
differential diagnosis
Final diagnosis altered
management
Nasopharyngeal
carcinoma Tuberculosis
5 (40) Patient died, lost to follow-up or
inadequate/unobtainable sample
Final diagnosis did not
affect management
NR
NR not relevant
Initial diagnosis Number of patients
Lymphoproliferative disorder (LPD) 34
LPD/hyper-reactive malarial splenomegaly (HMS) 23
Chronic lymphocytic leukaemia (CLL) 17
Myeloma 9
Hodgkin lymphoma 9
Infection/lymphoma 9
Acute lymphoblastic leukaemia 9
Metastatic carcinoma 7
Marginal zone lymphoma (MZL) 5
HMS 5
Diffuse large B-cell lymphoma 4
LPD/other malignancy 4
CLL/MZL 3
Tuberculosis 2
Follicular lymphoma 1
Rosai Dorfman 1
Other 2
No initial diagnosis given 5
Table 4 Initial diagnoses made
in Ghana
(/) differential diagnosis
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compare outcomes between, for example, patients who did
and did not have samples processed in the UK. However,
the retrospective audit of lymphoma patients provides an
indication of the extent to which patients could be
investigated locally and the range and preciseness of
diagnoses compared to the recommended international
lymphoma classification categories.
There are very few descriptions in the literature of
successful collaborations between wealthy and less wealthy
countries to improve the diagnosis of haematological
malignancies. Ours is the first study to focus on real-time
remote diagnosis for patients in Africa with suspected
LPDs. The only published collaboration to use remote
diagnosis on posted samples was between institutions in the
USA and El Salvador. This study aimed to describe clinical
and biological features of childhood leukaemia in El
Salvador and to develop effective treatment regimens.
Between 1994 and 1996, 153 patients were enrolled in the
study. Morphology and cytochemistry were performed
locally, and bone marrow samples were sent by post or
courier to the USA for immunophenotyping, DNA analysis
and molecular genetics. The programme was subsequently
extended to Honduras and Guatemala and was successful
primarily because it had been generated and part-funded by
an enthusiastic local team in El Salvador. Problems
encountered with the remote analysis of samples included
the inability to get repeat samples when results were
inconclusive, loss of samples and delays during transit
resulting in samples that were inadequate for testing. As the
number of samples increased, the techniques and expertise
were gradually transferred to El Salvador [10]. In our study,
we had a very low incidence of inadequate specimens
presumably due to the use of fixed trephine and lymph
node biopsies as opposed to fresh bone marrow aspirate or
peripheral blood samples.
Two other collaborations to improve the diagnosis and
management of childhood leukaemia involved three centres
in India linked with one in the USA and a partnership
between Nicaragua, Italy and Switzerland [11, 12]. These
collaborations provided local training rather than a remote
diagnostic service. Confirmation of the diagnosis of non-
Hodgkin lymphoma was carried out on samples from
Kuwait by an expert panel in Germany but this study was
retrospective and was therefore not able to directly
influence patient management [13].
An improved diagnostic system is only one component
in the pathway to improving clinical outcomes for patients
with LPDs in sub-Saharan Africa. Our study was limited to
the diagnosis of LPDs and was not designed to measure
impact on patient outcomes, which are influenced by many
factors beyond this diagnostic system. Patients in develop-
ing countries often have to pay for diagnostic tests and
treatment. This leads to sub-optimal care especially for the
poorest. In Africa, treatment protocols need to be tailored
not only to affordability but to availability of drugs and
supportive therapies such as platelet transfusions and
growth factors. Clinicians’ response to changes in diagnos-
tic services is also an important determinant of patient
outcomes.
As this was a feasibility study, the costs were met from
project funds. Before deciding whether or not to scale up a
remote diagnostic service, more research is needed to
determine the cost benefits from the perspective of both
the patient and the health services. Compared to the
existing service in Ghana, the benefits to the patients are
a more rapid and accurate process to confirm an LPD or
alternative diagnosis and the potential to receive the correct
treatment with subsequent positive health benefits. For the
health service, the benefits would include information about
the causes of lymphadenopathy and local epidemiology of
LPDs, which would enable better planning and allocation
of oncology resources.
If Ghana and other countries in sub-Saharan Africa are
to establish effective treatment programmes for LPDs, then
the ultimate aim must be to transfer the diagnostic
techniques and the skills to interpret them to institutions
in Africa [14]. Our feasibility study has demonstrated that it
is possible to set up a sophisticated diagnostic service for
patients in Ghana with suspected LPDs that enables patients
to be classified according to international standards. This
model for Ghana–UK collaboration provides a platform on
which to gradually build local capacity to operate an
international quality diagnostic service for LPDs. The study
has shown that transferring specific immunohistochemistry
technology for biopsies to Ghanaian institutions should be a
priority as this is a robust technique, which provides good
diagnostic information about LPDS and conditions that
may mimic LPDs. Transfer of technology needs to be
accompanied by development of medical, nursing and
paramedical expertise in LPDs, enhanced facilities for
supportive care for neutropenic patients and reliable,
adequate supplies of safe blood components [15].
Cancer is an important cause of morbidity and mortality in
countries in sub-Saharan Africa, and new initiatives such as
health insurance schemes are driving demand for better
quality diagnosis as well as providing more resources to treat
cancers. Collaborations between health care workers and
scientists in wealthy and less wealthy countries are an
excellent way to bridge the inequalities in cancer services
that exist between these countries. Developing countries gain
access to new techniques for diagnosis, resources to improve
patientmanagementandtrainingtoenhanceskillsandmorale.
Developed countries broaden their knowledge about cancers
and are provided with much better opportunities than are
available in their own country to reassess what is essential in
148 J Hematopathol (2009) 2:143–149cancer care and what can be adapted and streamlined [12].
Furthermore, establishment of international quality cancer
treatment units in developing countries will attract more
physicians and researchers and contribute significantly to
global knowledge about the clinical, biological and epide-
miological aspects of cancer [16].
Authors’ contributions EP was responsible for collecting patient
samples, coordinated link between institutions in Ghana and the UK
and contributed to the design, analysis and write-up of the study
(project was part of her MD thesis).
RO was responsible for coordinating diagnostic process at HMDS and
reporting results and contributed to the design, analysis and write-up
of the study.
GBA, OOS, IE and YD were the clinicians responsible for identifying
and managing study patients and providing clinical information and
contributed to the design and write-up of the study.
IB (guarantor) conceived the study, contributed to the design and
analysis and was responsible for drafting the paper.
Competing interests All authors have nothing to declare.
Role of the funding source Funding for this study was provided by
HMDS, the Liverpool School of Tropical Medicine. EP self-funded
her MD. Study sponsors had no role in study design; in the collection,
analysis and interpretation of data; in the writing of the report; and in
the decision to submit the paper for publication.
References
1. Swerdlow SH, Campo E, Lee Harris N, Jaffe ES, Pileri SA, Stein
H, Thiele J, Vardiman JW (2008) WHO classification of tumours.
Pathology and genetics of tumours of haematopoietic and
lymphoid tissues. IARC, Lyon
2. Lester JF, Dojcinov SD, Attanoos RL, O’Brien CJ, Maughan TS,
Toy ET, Poynton CH (2003) The clinical impact of expert
pathological review on lymphoma management: a regional
experience. Br J Haematol 123(3):463–468
3. Anderson JR, Armitage JO, Weisenburger DD (1998) Epidemiol-
ogy of the non-Hodgkin’s lymphomas: distributions of the major
subtypes differ by geographic locations. Non-Hodgkin’s Lympho-
ma classification project. Ann Oncol 9:717–720
4. Parkin DM, Pisani P, Ferlay J (1999) Global cancer statistics. CA
Cancer J Clin 49:33–64
5. Omoti CE, Awodu OA, Bazuaye GN (2007) Chronic lymphoid
leukaemia: clinico-haematological correlation and outcome in a
single institution in Niger Delta region of Nigeria. Int J Lab
Hematol 29(6):426–432
6. Othieno-Abinya NA, Abwao HO, Maina JM, Nyabola LO, Opiyo
A, Njuguna E, Ndege P, Musibi A (2004) Non-Hodgkin’s
lymphomas at Kenyatta the National Hospital Nairobi in the
1990’s. East Afr Med J 81(9):450–458
7. Obafunwa JO, Olomu IN, Onyia NJ (1992) Primary peripheral
lymphadenopathy in Jos, Nigeria. West Afr J Med 11(1):25–28
8. Bedu-Addo G, Bates I (2002) Causes of massive tropical
splenomegaly in Ghana. Lancet 360:449–454
9. Stephens E, Bates I, Bedu-Addo G, Opare Sem K, Ekem I, Dei Y,
O’Connor SJM, Evans PAS, Rollett RA, Owen RG (2007)
Tropical splenic lymphoma: detailed clinico-pathological assess-
ment in 19 Ghanaian patients. Br J Haematol 137S1:19
10. Bonilla M, Moreno N, Marina N, de Reyes G, Shurtleff SA,
Downing JR, Behm FG, Harrison PL, Ribeiro RC, Pena O, Crist
WM, Antillon FG (2000) Acute lymphoblastic leukemia in a
developing country: preliminary results of a nonrandomized
clinical trial in El Salvador. J Pediatr Hematol Oncol 22(6):495–
501
11. Magrath I, Shanta V, Advani S, Adde M, Arya LS, Banavali S,
Bhargava M, Bhatia K, Gutiérrez M, Liewehr D, Pai S, Sagar TG,
Venzon D (2005) Treatment of acute lymphoblastic leukaemia in
countries with limited resources; lessons from use of a single
protocol in India over a twenty year period. Eur J Cancer
41:1570–1583
12. Masera G, Baez F, Biondi A, Cavalli F, Conter V, Flores A,
Fontana G, Fossati Bellani F, Lanfranco P, Malta A, Mendez G,
Ocampo E, Pacheco C, Riva L, Sala A, Silva F, Sessa C, Tognoni
G (1998) North–South twinning in paediatric haemato-oncology:
the La Mascota programme, Nicaragua. Lancet 352:1293–1296
13. Temmim L, Baker H, Al-Jarallah MA, Manguno H, Madda JP,
Sinowatz F (2004) Clinical characteristics and pathological
classification of non-hodgkin’s lymphoma in Kuwait. Results of
a collaborative study with the International Lymphoma Study
Group (ILSG). Leuk Lymphoma 45(9):1865–1871
14. Howard SC, Ribeiro RC, Pui CH (2005) Strategies to improve
outcomes of children with cancer in low-income countries. Eur J
Cancer 41(11):1584–1587
15. Eden T (2002) Translation of cure for acute lymphoblastic
leukaemia to all children. Br J Haematol 118:945–951
16. Greenberg PL, Gordeuk V, Issaragrisil S, Siritanaratkul N,
Fucharoen S, Ribeiro PC (2001) Major hematologic diseases in
the developing world—new aspects of diagnosis and management
of thalassemia, malarial anemia, and acute leukemia. Hematology
Am Soc Hematol Educ Program 479–498
J Hematopathol (2009) 2:143–149 149